Targetable pathogenic mechanisms in nasal polyposis
Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a challenging disease entity with significant rates of recurrence following appropriate medical and surgical therapy. Recent approval of targeted biologics in CRSwNP compels deeper understanding of underlying disease pathophysiology. Both...
Gespeichert in:
| Veröffentlicht in: | International forum of allergy & rhinology 2021-08, Vol.11 (8), p.1220-1234 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1234 |
|---|---|
| container_issue | 8 |
| container_start_page | 1220 |
| container_title | International forum of allergy & rhinology |
| container_volume | 11 |
| creator | Schneider, Alexander L. Schleimer, Robert P. Tan, Bruce K. |
| description | Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a challenging disease entity with significant rates of recurrence following appropriate medical and surgical therapy. Recent approval of targeted biologics in CRSwNP compels deeper understanding of underlying disease pathophysiology. Both of the approved biologics for CRSwNP modulate the type 2 inflammatory pathway, and the majority of drugs in the clinical trials pathway are similarly targeted. However, there remain multiple other pathogenic mechanisms relevant to CRSwNP for which targeted therapeutics already exist in other inflammatory diseases that have not been studied directly. In this article we summarize pathogenic mechanisms of interest in CRSwNP and discuss the results of ongoing clinical studies of targeted therapeutics in CRSwNP and other related human inflammatory diseases. |
| doi_str_mv | 10.1002/alr.22787 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8316260</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2497096378</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4437-28d4b79bd43ef848dc55842e22cdaf4edd85f80cb7c6694e5a29722f69daef423</originalsourceid><addsrcrecordid>eNp1kU1LAzEQhoMoKurBPyALXvRQzeZ7L4IUv6AgiJ5DNjvbRrKbNWmV_nuj1aKCc8nAPDxM5kXosMRnJcbk3Ph4RohUcgPtEszISFSKba57KXbQQUrPOBcvOS_lNtqhVIg85ruIPpo4hbmpPRSDmc_CFHpniw7szPQudalwfdGbZHwxBL8cQnJpH221xic4-Hr30NP11eP4djS5v7kbX05GljEqR0Q1rJZV3TAKrWKqsZwrRoAQ25iWQdMo3ipsa2mFqBhwQypJSCuqxkDLCN1DFyvvsKg7aCz082i8HqLrTFzqYJz-PendTE_Dq1a0FETgLDj5EsTwsoA0151LFrw3PYRF0oRVEleCSpXR4z_oc1jEPn9PE56vpqigZaZOV5SNIaUI7XqZEuuPNHROQ3-mkdmjn9uvye_bZ-B8Bbw5D8v_Tfpy8rBSvgPRLpPs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2555183631</pqid></control><display><type>article</type><title>Targetable pathogenic mechanisms in nasal polyposis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Schneider, Alexander L. ; Schleimer, Robert P. ; Tan, Bruce K.</creator><creatorcontrib>Schneider, Alexander L. ; Schleimer, Robert P. ; Tan, Bruce K.</creatorcontrib><description>Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a challenging disease entity with significant rates of recurrence following appropriate medical and surgical therapy. Recent approval of targeted biologics in CRSwNP compels deeper understanding of underlying disease pathophysiology. Both of the approved biologics for CRSwNP modulate the type 2 inflammatory pathway, and the majority of drugs in the clinical trials pathway are similarly targeted. However, there remain multiple other pathogenic mechanisms relevant to CRSwNP for which targeted therapeutics already exist in other inflammatory diseases that have not been studied directly. In this article we summarize pathogenic mechanisms of interest in CRSwNP and discuss the results of ongoing clinical studies of targeted therapeutics in CRSwNP and other related human inflammatory diseases.</description><identifier>ISSN: 2042-6976</identifier><identifier>EISSN: 2042-6984</identifier><identifier>DOI: 10.1002/alr.22787</identifier><identifier>PMID: 33660425</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>biologic therapies ; Biological Products - therapeutic use ; Chronic Disease ; chronic rhinosinusitis with nasal polyps ; Clinical trials ; Humans ; Inflammatory diseases ; Nasal Polyps ; Pathophysiology ; Polyposis ; Polyps ; Rhinitis ; Rhinitis - drug therapy ; Rhinosinusitis ; Sinusitis ; Sinusitis - drug therapy ; type 2 inflammation</subject><ispartof>International forum of allergy & rhinology, 2021-08, Vol.11 (8), p.1220-1234</ispartof><rights>2021 ARS‐AAOA, LLC</rights><rights>2021 ARS-AAOA, LLC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4437-28d4b79bd43ef848dc55842e22cdaf4edd85f80cb7c6694e5a29722f69daef423</citedby><cites>FETCH-LOGICAL-c4437-28d4b79bd43ef848dc55842e22cdaf4edd85f80cb7c6694e5a29722f69daef423</cites><orcidid>0000-0001-9013-646X ; 0000-0001-9210-5050</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Falr.22787$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Falr.22787$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33660425$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schneider, Alexander L.</creatorcontrib><creatorcontrib>Schleimer, Robert P.</creatorcontrib><creatorcontrib>Tan, Bruce K.</creatorcontrib><title>Targetable pathogenic mechanisms in nasal polyposis</title><title>International forum of allergy & rhinology</title><addtitle>Int Forum Allergy Rhinol</addtitle><description>Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a challenging disease entity with significant rates of recurrence following appropriate medical and surgical therapy. Recent approval of targeted biologics in CRSwNP compels deeper understanding of underlying disease pathophysiology. Both of the approved biologics for CRSwNP modulate the type 2 inflammatory pathway, and the majority of drugs in the clinical trials pathway are similarly targeted. However, there remain multiple other pathogenic mechanisms relevant to CRSwNP for which targeted therapeutics already exist in other inflammatory diseases that have not been studied directly. In this article we summarize pathogenic mechanisms of interest in CRSwNP and discuss the results of ongoing clinical studies of targeted therapeutics in CRSwNP and other related human inflammatory diseases.</description><subject>biologic therapies</subject><subject>Biological Products - therapeutic use</subject><subject>Chronic Disease</subject><subject>chronic rhinosinusitis with nasal polyps</subject><subject>Clinical trials</subject><subject>Humans</subject><subject>Inflammatory diseases</subject><subject>Nasal Polyps</subject><subject>Pathophysiology</subject><subject>Polyposis</subject><subject>Polyps</subject><subject>Rhinitis</subject><subject>Rhinitis - drug therapy</subject><subject>Rhinosinusitis</subject><subject>Sinusitis</subject><subject>Sinusitis - drug therapy</subject><subject>type 2 inflammation</subject><issn>2042-6976</issn><issn>2042-6984</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1LAzEQhoMoKurBPyALXvRQzeZ7L4IUv6AgiJ5DNjvbRrKbNWmV_nuj1aKCc8nAPDxM5kXosMRnJcbk3Ph4RohUcgPtEszISFSKba57KXbQQUrPOBcvOS_lNtqhVIg85ruIPpo4hbmpPRSDmc_CFHpniw7szPQudalwfdGbZHwxBL8cQnJpH221xic4-Hr30NP11eP4djS5v7kbX05GljEqR0Q1rJZV3TAKrWKqsZwrRoAQ25iWQdMo3ipsa2mFqBhwQypJSCuqxkDLCN1DFyvvsKg7aCz082i8HqLrTFzqYJz-PendTE_Dq1a0FETgLDj5EsTwsoA0151LFrw3PYRF0oRVEleCSpXR4z_oc1jEPn9PE56vpqigZaZOV5SNIaUI7XqZEuuPNHROQ3-mkdmjn9uvye_bZ-B8Bbw5D8v_Tfpy8rBSvgPRLpPs</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Schneider, Alexander L.</creator><creator>Schleimer, Robert P.</creator><creator>Tan, Bruce K.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9013-646X</orcidid><orcidid>https://orcid.org/0000-0001-9210-5050</orcidid></search><sort><creationdate>202108</creationdate><title>Targetable pathogenic mechanisms in nasal polyposis</title><author>Schneider, Alexander L. ; Schleimer, Robert P. ; Tan, Bruce K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4437-28d4b79bd43ef848dc55842e22cdaf4edd85f80cb7c6694e5a29722f69daef423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>biologic therapies</topic><topic>Biological Products - therapeutic use</topic><topic>Chronic Disease</topic><topic>chronic rhinosinusitis with nasal polyps</topic><topic>Clinical trials</topic><topic>Humans</topic><topic>Inflammatory diseases</topic><topic>Nasal Polyps</topic><topic>Pathophysiology</topic><topic>Polyposis</topic><topic>Polyps</topic><topic>Rhinitis</topic><topic>Rhinitis - drug therapy</topic><topic>Rhinosinusitis</topic><topic>Sinusitis</topic><topic>Sinusitis - drug therapy</topic><topic>type 2 inflammation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schneider, Alexander L.</creatorcontrib><creatorcontrib>Schleimer, Robert P.</creatorcontrib><creatorcontrib>Tan, Bruce K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International forum of allergy & rhinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schneider, Alexander L.</au><au>Schleimer, Robert P.</au><au>Tan, Bruce K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targetable pathogenic mechanisms in nasal polyposis</atitle><jtitle>International forum of allergy & rhinology</jtitle><addtitle>Int Forum Allergy Rhinol</addtitle><date>2021-08</date><risdate>2021</risdate><volume>11</volume><issue>8</issue><spage>1220</spage><epage>1234</epage><pages>1220-1234</pages><issn>2042-6976</issn><eissn>2042-6984</eissn><abstract>Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a challenging disease entity with significant rates of recurrence following appropriate medical and surgical therapy. Recent approval of targeted biologics in CRSwNP compels deeper understanding of underlying disease pathophysiology. Both of the approved biologics for CRSwNP modulate the type 2 inflammatory pathway, and the majority of drugs in the clinical trials pathway are similarly targeted. However, there remain multiple other pathogenic mechanisms relevant to CRSwNP for which targeted therapeutics already exist in other inflammatory diseases that have not been studied directly. In this article we summarize pathogenic mechanisms of interest in CRSwNP and discuss the results of ongoing clinical studies of targeted therapeutics in CRSwNP and other related human inflammatory diseases.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33660425</pmid><doi>10.1002/alr.22787</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0001-9013-646X</orcidid><orcidid>https://orcid.org/0000-0001-9210-5050</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2042-6976 |
| ispartof | International forum of allergy & rhinology, 2021-08, Vol.11 (8), p.1220-1234 |
| issn | 2042-6976 2042-6984 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8316260 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | biologic therapies Biological Products - therapeutic use Chronic Disease chronic rhinosinusitis with nasal polyps Clinical trials Humans Inflammatory diseases Nasal Polyps Pathophysiology Polyposis Polyps Rhinitis Rhinitis - drug therapy Rhinosinusitis Sinusitis Sinusitis - drug therapy type 2 inflammation |
| title | Targetable pathogenic mechanisms in nasal polyposis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T16%3A17%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targetable%20pathogenic%20mechanisms%20in%20nasal%20polyposis&rft.jtitle=International%20forum%20of%20allergy%20&%20rhinology&rft.au=Schneider,%20Alexander%20L.&rft.date=2021-08&rft.volume=11&rft.issue=8&rft.spage=1220&rft.epage=1234&rft.pages=1220-1234&rft.issn=2042-6976&rft.eissn=2042-6984&rft_id=info:doi/10.1002/alr.22787&rft_dat=%3Cproquest_pubme%3E2497096378%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2555183631&rft_id=info:pmid/33660425&rfr_iscdi=true |